The combination of an Average People Pillar rating and a Below Average Process Pillar rating limit Rydex Biotechnology C to a Morningstar Quantitative Rating of Negative. Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the most expensive quintile among peers.
- NAV / 1-Day Return 49.47 / 0.57 %
- Total Assets 134.9 Mil
-
Adj. Expense Ratio
- Expense Ratio 2.360%
- Distribution Fee Level High
- Share Class Type Level Load
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment 2,500
- Status Open
- TTM Yield 0.00
- Turnover 65%
Morningstar’s Analysis RYCFX
Will RYCFX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.